Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epirubicin · 1 trial · 1 indication
A participant was considered to have had a DFS event if there was evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.
| Arm | Type | Description |
|---|---|---|
| Arm A: EC-T | ACTIVE_COMPARATOR | Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles. |
| Arm B: ET-X | EXPERIMENTAL | Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles. |
| Name | Type | Description |
|---|---|---|
| Docetaxel | DRUG | - |
| Capecitabine | DRUG | - |
| Epirubicin | DRUG | - |
| Cyclophosphamide | DRUG | - |
Inclusion Criteria: * Written informed consent. * Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3). Tumours must be HER2 negative. Time window between surgery and study randomization must be less than 60 days. * Surgery must consist of mastectomy or conservative surg...
Top 20 of 92 competitors
Epirubicin is an oncology small molecule being studied for use in breast cancer. It is currently in Phase 3 clinical development as an adjuvant chemotherapy for patients with node positive operable breast cancer. The drug is being developed by Sanofi.
Epirubicin is being developed by Sanofi, a company traded on the stock exchange under the ticker SNY. The drug is currently in Phase 3 clinical trials for the treatment of breast cancer.
Epirubicin is in Phase 3 clinical development. It is an investigational drug being studied for breast cancer and has not yet been approved by regulatory authorities. A Phase 3 trial for the drug has been completed.
Epirubicin has been studied in a Phase 3 clinical trial with the identifier NCT00129935. This trial, titled "EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer," enrolled 1,384 female patients aged 18 years and older in Spain. The trial has been completed.
Epirubicin is a distinct drug being studied for breast cancer. It is being evaluated in a clinical trial that compares different chemotherapy regimens, including epirubicin combined with other agents, for the adjuvant treatment of node positive operable breast cancer.